Compare iShares Russell 2000 ETF (IWM) vs Merck & Co., Inc. (MRK) Price & Performance

iShares Russell 2000 ETFTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs Merck & Co., Inc. — how do they compare? iShares Russell 2000 ETF trades at $302.98, while Merck & Co., Inc. trades at $129.51 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals.

	IWM	MRK
52-Week High	$301.69	$131.84
52-Week Low	$225.45	$77.60
Market Cap	—	$321.77B
Sector	—	Health
Enterprise Value	—	$368.53B
Dividend Yield	—	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IWM

SPSM ETF offers cheaper, more profitable small-cap exposure than IWM with better long-term returns.24/7 Wall Street · 3 days agoBullish Leveraged small-cap ETF TNA soars 117% in a year but loses over 5 years due to volatility decay.24/7 Wall Street · 4 days agoNeutral View details →

MRK

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 4 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 6 hours agoBullish Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 1 day agoBearish View details →

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.